Benzodiazepines have largely been used in sleep disorders due to their anxiolytic and hypnotic action. Easy handling, few side effects 43, 6 0 , and efficacy justify this preference. Although most studies in the literature concern insomnia in adults, those drugs have also been used in sleep disorders in children 21 . Among benzodiazepines, flurazepam is of great interest for its prolonged action, minimum side effects, low sedative action and minimum inducing effect over the hepatic microsome enzimatic system; furthermore, it can act for longer periods, compared to other hypnotic prugs 11,38 . Although it is proved to be efficient in adults and also indicated for children 4 6 , there is a lack of controlled studies and with adequate statistical analysis in childhood. In the present study we tried to evaluate the middle: term action of flurazepam in sleep disorders in infancy and childhood, compared with placebo.
together with the drug studied. All of them had their seizures controlled for over one year.
The disorders presented were: sleepwalking, sleep-talking, sleep-related bruxism, sleep terror, excessive movements when sleeping, sleep-related headbanging and insomnia (Table 2) . Two or more disturbances were observed in 32 (80%); three or more disturbances in 22 (65.0%) and in these, the most frequent triad was somnambulism, sleep-talking and excessive movements during sleep, observed in 12 cases.
Excessive movements when sleeping 29 Out of the total sampling, 35 (87.5%) were administered flurazepam and placebo isolately; the other 5 (12.5%) received them associated with the anticonvulsants. In all cases, flurazepam was the first and only drug with a hypnotic purpose. All parents and patients were informed that a test would be carried out with two different drugs and they gave their consent. All of them received initially placebo in the dose of half a tablet at bedtime for two weeks followed by flurazepam, also half a tablet at bedtime for two more weeks. Each tablet of placebo contained 200mg of ferrous sulfate. Each tablet of flurazepam contained 30mg of the drug. The interval between the clinical assessments was two weeks for all patients and they all underwent, at first, routine electroencephalogram (EEG) and complete blood count.
The evaluation of the results was carried out by using the following designation: no response (N) when the patients presented no improvement in the frequency of the sleep disorders or when there was a worsening of the symptoms; regular (R) when there was a decrease of 50% or less; good (G) when the reduction was between 51 and 75%; very good (VG) when between 76 and 100%. In the statistical calculations we considered initially as equal the difference intervals among the several degrees of improvement (VG,G,R,N) and we observed through the Signal test 612 the difference between the results with placebo and with flurazepam. This calculation was carried out for each disorder separately. Whenever the sample had less than 25 individuals, we compared the difference by the Binomial test 62 and when it had more than 25 we did it by Normal Distribution 62. As a second approach, trying to observe better the relations of results we performed a comparison of the frequency of differences. In this comparison, whenever the expected frequency was greater or equal to 5 we used the test of χ2^ and when smaller than 5, the Binomial test.
RESULTS
In 24 cases of sleepwalking, 18 had an improvement when passing from placebo to flurazepam (Table 3) which is highly significant (p< 0.001). When we compared the number of patients who remained unaltered with the ones who improved, we noticed an important difference (0.02> p> 0.001). The difference between those who had a remarkable improvement when shifting from Ν with placebo to VG with the drug and the others was not significant.
We observed 26 cases of sleep-talking and noticed improvement in 23 when changing from placebo to the drug (Table 4) , which is highly significant (p< 0.0001). The difference between the number of children who improved and the ones without alte rations was remarkable (p< 0.001) It must be pointed out that 18 out of the 25 cases had a remarkable improvement passing from Ν with placebo to VG with the drug which is significant when compared with other 8 patients (0.05> p> 0.02) Among the 15 patients with bruxism, 9 presented improvement when passing from placebo to the hypnotic drug (Table 6) , which is an important difference (pt= 0.002). The comparison by test between those who did not show alterations and all the ones who improved, as well as the comparison between those with little improvement and the ones in which the improvement was remarkable, was not significant.
Sleep terror was observed in 9 patients, 5 of which improved when changing to flurazepam (p>= 0.031), which is an important result since none of them presented better results with placebo (Table 7) . On the other hand, there was no difference between the number of children who remained unaltered (4) and the ones who improved (5) when passing from the placebo to the drug.
Excessive movement when sleeping was the most frequent complaint; it was reported in 29 patients out of which 27 improved when changed from placebo to flurazepam (Table 5) , which is significant (p< 0.00003). It was significant the difference between the ones who had Ν or R with placebo and G or VG with the benzodiazepine, i.e., the ones who had a remarkable improvement in relation to the others (p< 0.001). Patients who presented sleep-related headbanging and insomnia were very few and do not represent a statistical analysis.
In the two cases with sleep-related headbanging, one presented improvement with flurazepam and no improvement with placebo. The three cases with insomnia revealed results VG with flurazepam and Ν with placebo.
Side effects were reported by the parents in three cases with placebo and six cases with flurazepam (Table 8) The children who showed these effects with placebo were 2,4 and 12 years old; the ones with the drug were 1,2,3,5,7 and 8 years old. Therefore, the age of the patients was not correlated. In the total of side effects, flurazepam had to be discontinued in 2 cases (3 and 8 years old). These patients presented mild vomiting and excessive drowsiness during the first three days which led us to reduce the dose for 7.5mg daily but, as this manifestation still persisted in the three following days, the drug was discontinued.
General clinical examination and neurologic tests were normal in all cases studied.
The EEG performed in all patients before the test was normal in 35 (87.5%); in the Complete blood count performed in all patients showed to be normal in 24 (60.0%) and in the others we observed mild anemia in 13 (32.5%) and only eosinophilia in 
SUMMARY
The clinically observed results in 40 patients, from 1 to 15 years old, presenting sleep disturbances, in a comparative and statistically approached study of flurazepam 15mg daily against placebo, are reported. Placebo was administered, followed by the drug, during 14 days each. The chief complaints were sleepwalking, sleep-talking, sleep terror, sleep-related bruxism, sleep--related headbanging, insomnia and excessive movements during sleep. A significant effect of flurazepam on sleepwalking, sleep-talking, bruxism, sleep terror and excessive movement during sleep, was observed. The insomniac and headbanging patients were not enough for statistical analysis. Flurazepam side effects were excessive drowsiness during daytime in 3 cases; irritability, 3 cases; nausea and vomiting, 2 cases, and were not correlated with age. Placebo side effects were similar, except for nausea and vomiting which were not observed. It was necessary to discontinue flurazepam in 2 cases, because of excessive drowsiness during daytime, which did not improve when reducing the dose. 
